| Revision as of 21:09, 10 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank', 'ChEMBL').← Previous edit |
Latest revision as of 06:39, 25 October 2024 edit undo76.174.0.57 (talk) Cats. |
| (35 intermediate revisions by 26 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Pharmaceutical drug}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 407951707 |
|
| verifiedrevid = 460027190 |
|
| IUPAC_name = 2-methyspiro (1,3- oxathiolane- 5,3) quinuclidine |
|
|
|
| IUPAC_name = (2''R'',2''R'')-2'-Methylspirooctane-2,5'-oxathiolane] |
|
| image = Cevimeline.svg |
|
| image = Cevimeline.svg |
|
|
| width = 175 |
|
| image2 = Cevimeline 3D.png |
|
| image2 = Cevimeline 3D.png |
|
|
|
|
| Line 16: |
Line 19: |
|
| legal_UK = <!-- GSL / P / POM / CD --> |
|
| legal_UK = <!-- GSL / P / POM / CD --> |
|
| legal_US = <!-- OTC / Rx-only --> |
|
| legal_US = <!-- OTC / Rx-only --> |
|
| legal_status = Rx only |
|
| legal_status = Rx-only |
|
| routes_of_administration = Oral |
|
| routes_of_administration = ] (]) |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = < 20% |
|
| protein_bound = <20% |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
| CASNo_Ref = {{cascite|correct|CAS}} |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 107233-08-9 |
|
| CAS_number = 107233-08-9 |
| Line 43: |
Line 45: |
|
| KEGG = D07667 |
|
| KEGG = D07667 |
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
| ChEMBL = <!-- blanked - oldvalue: 1201267 --> |
|
| ChEMBL = 1201267 |
|
|
| ChEBI_Ref = {{ebicite|changed|EBI}} |
| ⚫ |
| C=10 | H=17 | N=1 | O=1 | S=1 |
|
|
|
| ChEBI = 3568 |
|
| molecular_weight = 489.565 g/mol |
|
|
|
|
|
|
<!--Chemical data--> |
|
⚫ |
| C=10 | H=17 | N=1 | O=1 | S=1 |
|
| smiles = O1(SC12CN3CCC2CC3)C |
|
| smiles = O1(SC12CN3CCC2CC3)C |
|
| InChI = 1/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 |
|
|
| InChIKey = WUTYZMFRCNBCHQ-PSASIEDQBZ |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 |
|
| StdInChI = 1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 |
| Line 55: |
Line 58: |
|
}} |
|
}} |
|
|
|
|
|
'''Cevimeline''' ('''Evoxac''') is a ] and ],<ref name="pmid15234277">{{cite journal |author=Ono M, Takamura E, Shinozaki K, ''et al.'' |title=Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study |journal=Am. J. Ophthalmol. |volume=138 |issue=1 |pages=6–17 |year=2004 |month=July |pmid=15234277 |doi=10.1016/j.ajo.2004.02.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002939404001369}}</ref> with particular effect on ]s. It is used in the treatment of ] associated with ]. |
|
'''Cevimeline''' (trade name '''Evoxac''') is a synthetic analog of the natural alkaloid ] with a particular agonistic effect on ] and ]s. It is used in the treatment of ] and ]. |
|
|
|
|
|
== Mechanism of action == |
|
== Medical uses == |
|
|
Cevimeline is used in the treatment of ] (dry mouth)<ref name="Ono_2004">{{cite journal | vauthors = Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, Tsubota K | title = Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study | journal = American Journal of Ophthalmology | volume = 138 | issue = 1 | pages = 6–17 | date = July 2004 | pmid = 15234277 | doi = 10.1016/j.ajo.2004.02.010 }}</ref><ref name="Fox_2019">{{cite book | vauthors = Fox RI, Fox CM | chapter = Management of Sjögren's |title=Dubois' Lupus Erythematosus and Related Syndromes|publisher=] |year=2019 |isbn=978-0-323-47927-1|edition=9th|pages=745-758|language=en |doi=10.1016/B978-0-323-47927-1.00060-8}}</ref> and ].<ref name="Ono_2004" /> It increases the production of saliva.<ref name="Fox_2019" /> |
|
|
|
| ⚫ |
By activating the M<sub>3</sub> receptors of the ], cevimeline stimulates secretion by the ]s, thereby alleviating dry mouth. |
|
|
|
|
|
|
== Side effects == |
|
== Side effects == |
|
⚫ |
Known side effects include ], ], ], excessive ], ], ], ], ], ], ]es, ], and ].<ref>{{cite web | url = http://www.medicinenet.com/cevimeline-oral/article.htm] | work = MedicineNet | title = Cevimeline | access-date = 12 October 2007 }}</ref> |
|
|
|
| ⚫ |
Known side effects include ], ], ], excessive ], ], ], ], ], ], ]es, ], and ].<ref> MedicineNet: Cevimeline. Accessed 10/12/2007</ref> |
|
|
|
|
|
|
Contraindications include ] and ].{{citation needed|date=December 2010}} |
|
Contraindications include ] and ].{{citation needed|date=December 2010}} |
|
|
|
|
|
== Mechanism of action == |
|
⚫ |
Cevimeline is a cholinergic agonist.<ref name="Fox_2019" /> It has a particular effect on ] and ]s.<ref name="Fox_2019" /> By activating the M<sub>3</sub> receptors of the ], cevimeline stimulates secretion by the ]s, thereby alleviating dry mouth. |
|
|
|
|
|
== See also == |
|
|
* ] — a similar parasympathomimetic medication for dry mouth (]) |
|
|
* ] — a similar muscarinic parasympathomimetic with longer-lasting effect |
|
|
|
|
|
== References == |
|
== References == |
| Line 71: |
Line 79: |
|
|
|
|
|
== External links == |
|
== External links == |
|
* |
|
* |
|
|
|
|
|
|
{{Muscarinic acetylcholine receptor modulators}} |
|
{{Cholinergics}} |
|
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
] |
|
] |
|
|
] |
|
] |
|
] |
|
|
|
|
] |
|